<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640002</url>
  </required_header>
  <id_info>
    <org_study_id>FR-473218</org_study_id>
    <nct_id>NCT01640002</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder</brief_title>
  <official_title>A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitário Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's a double blind, placebo controlled study to assess the efficacy of Propantheline Bromide
      to treat overactive bladder (OAB) in HTLV 1 infected patients.

      We think that the treatment of the OAB with Propantheline could reduce nocturia and frequency
      in sixty percent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to
      treat overactive bladder (OAB) in HTLV 1 infected patients

      Treatment Group Propantheline Bromide: 15mg, three times daily for 08 weeks.

      Control Group Placebo 03 times daily

      Case definition Clinically defined OAB patients (ICS criteria), infected by HTLV-1. Frequency
      was defined as more than 08 daytime voids. Nocturia was defined as more than 02 voids after
      sleeping.

      Inclusion criteria More than 18 year. HTLV-1 infected patients with overactive bladder.
      Negative culture of urine. Without neurological impairment.

      Exclusion criteria Persistently positive urine culture

      History of:

      Allergy to medication, head or spinal trauma. Head and neck, neurological,spinal, lower
      abdominal or pelvic surgery. Stroke. Users of urinary catheters.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improve in Overactive bladder symptoms score</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in nocturia and urgency</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Overactive Bladder Associated With HTLV-1</condition>
  <arm_group>
    <arm_group_label>Propantheline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propantheline Bromide</intervention_name>
    <description>15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.</description>
    <arm_group_label>Propantheline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HTLV-1 infection

          -  More than 18 years

          -  Negative urine culture

          -  No neurological damage

        Exclusion Criteria:

          -  Diabetes

          -  Persistently positive urine culture

          -  Pelvic, head, urological or gynecological surgery

          -  Stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Abraão Carneiro Neto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service of Imunology - Universitary Hospital Prof. Edgard Santos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Abraão Carneiro Neto</last_name>
    <phone>55+71+8149-1252</phone>
    <email>abraao.neto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service of Imunology - Universitary Hospital Prof. Edgard Santos</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40110-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Abraão Carneiro Neto</last_name>
      <phone>557132838392</phone>
      <email>abraao.neto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Edgard Marcelino Carvalho Filho</last_name>
      <email>imuno@ufba.br</email>
    </contact_backup>
    <investigator>
      <last_name>Edgard Marcelino Carvalho Filho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rocha PN, Rehem AP, Santana JF, Castro N, Muniz AL, Salgado K, Rocha H, Carvalho EM. The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study. BMC Infect Dis. 2007 Mar 12;7:15.</citation>
    <PMID>17352816</PMID>
  </reference>
  <reference>
    <citation>Poetker SK, Porto AF, Giozza SP, Muniz AL, Caskey MF, Carvalho EM, Glesby MJ. Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. J Clin Virol. 2011 May;51(1):54-8. doi: 10.1016/j.jcv.2011.02.004. Epub 2011 Mar 8.</citation>
    <PMID>21388871</PMID>
  </reference>
  <reference>
    <citation>Caskey MF, Morgan DJ, Porto AF, Giozza SP, Muniz AL, Orge GO, Travassos MJ, Barrón Y, Carvalho EM, Glesby MJ. Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses. 2007 Mar;23(3):365-71.</citation>
    <PMID>17411369</PMID>
  </reference>
  <reference>
    <citation>Gomes I, Melo A, Proietti FA, Moreno-Carvalho O, Loures LA, Dazza MC, Said G, Larouzé B, Galvão-Castro B. Human T lymphotropic virus type I (HTLV-I) infection in neurological patients in Salvador, Bahia, Brazil. J Neurol Sci. 1999 May 1;165(1):84-9.</citation>
    <PMID>10426153</PMID>
  </reference>
  <reference>
    <citation>Garlet GP, Giozza SP, Silveira EM, Claudino M, Santos SB, Avila-Campos MJ, Martins W Jr, Cardoso CR, Trombone AP, Campanelli AP, Carvalho EM, Silva JS. Association of human T lymphotropic virus 1 amplification of periodontitis severity with altered cytokine expression in response to a standard periodontopathogen infection. Clin Infect Dis. 2010 Feb 1;50(3):e11-8. doi: 10.1086/649871.</citation>
    <PMID>20038241</PMID>
  </reference>
  <reference>
    <citation>Tannus M, Tanajura D, Sundberg MA, Oliveira P, Castro N, Santos AM. Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP? Case Rep Med. 2011;2011:289389. doi: 10.1155/2011/289389. Epub 2011 Apr 13.</citation>
    <PMID>21541226</PMID>
  </reference>
  <reference>
    <citation>Thüroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, Heidler H, Madersbacher H, Melchior H, Schäfer W, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991 Apr;145(4):813-6; discussion 816-7.</citation>
    <PMID>2005707</PMID>
  </reference>
  <reference>
    <citation>Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011 Oct;78(4):768-73. doi: 10.1016/j.urology.2011.06.020.</citation>
    <PMID>21855969</PMID>
  </reference>
  <results_reference>
    <citation>Castro NM, Rodrigues W Jr, Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology. 2007 May;69(5):813-8.</citation>
    <PMID>17482910</PMID>
  </results_reference>
  <results_reference>
    <citation>Oliveira P, Castro NM, Muniz AL, Tanajura D, Brandão JC, Porto AF, Carvalho EM. Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. Urology. 2010 May;75(5):1100-3. doi: 10.1016/j.urology.2009.11.041. Epub 2010 Feb 26.</citation>
    <PMID>20189229</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitário Professor Edgard Santos</investigator_affiliation>
    <investigator_full_name>Jose Abraao Carneiro Neto</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>HTLV-1</keyword>
  <keyword>Propantheline</keyword>
  <keyword>anticholinergic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Propantheline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

